Anzeige
❌
Mehr »
Dienstag, 20.10.2026 - Börsentäglich über 12.000 News
Lithium vor 2022. Kernkraft vor dem Comeback. Tiefseebergbau jetzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
VT

WKN: A3EWWY | ISIN: US92859E2072 | Ticker-Symbol:
NASDAQ
20.10.26 | 19:44
0,133 US-Dollar
-1,33 % -0,002
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
VIVOS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
VIVOS THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur VIVOS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17:50SOD SCIENCES INC.: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test271Partnership unites the ReBalU Protocol, Vivos's sleep platform, and a new test for cells primed for chronic disease, reaching nearly 500,000 chronic-disease patients VERO BEACH, FL / ACCESS Newswire...
► Artikel lesen
MoVivos Therapeutics acquires stake in SOD Sciences1
MoVivos Therapeutics erwirbt Beteiligung an SOD Sciences1
MoVivos Therapeutics, Inc: Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel1
DoVivos Therapeutics to acquire minority stake in SOD Sciences in $12M stock transaction2
DoVivos Therapeutics, Inc: Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test1
VIVOS THERAPEUTICS Aktie jetzt für 0€ handeln
DoVivos Therapeutics, Inc. - 8-K, Current Report3
01.10.Vivos Therapeutics, Inc. - 8-K, Current Report-
29.09.Vivos Therapeutics plant jährliche Kostensenkungen von 3,6 Millionen US-Dollar1
29.09.Vivos Therapeutics, Inc: Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives244LITTLETON, Colo., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and...
► Artikel lesen
01.09.Vivos Therapeutics, Inc.: Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference827Littleton, Colorado--(Newsfile Corp. - September 1, 2026) - Vivos Therapeutics, Inc. (NASDAQ: VVOS) ("Vivos" or the "Company"), a leading medical technology and healthcare services company focused on...
► Artikel lesen
28.08.Vivos Therapeutics, Inc: Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center6
25.08.Vivos Therapeutics, Inc: Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers1
21.08.Vivos Therapeutics, Inc. - 8-K, Current Report3
20.08.Vivos Therapeutics opens Henderson facility with $10M capacity1
20.08.Vivos Therapeutics, Inc: Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment1
18.08.Vivos Therapeutics: Service Revenue Nearly Doubles To $3.8 Million While Product Revenue Falls 28%4
17.08.Vivos Therapeutics GAAP EPS of -$0.31 misses by $0.01, revenue of $5.15M misses by $0.99M1
15.08.Vivos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript2
14.08.Vivos Therapeutics steigert Umsatz im zweiten Quartal 2026 um 35 %1
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1